HK1143154A1 - 作為蛋白激酶 抑制劑的吡咯並 嘧啶衍生物 - Google Patents
作為蛋白激酶 抑制劑的吡咯並 嘧啶衍生物Info
- Publication number
- HK1143154A1 HK1143154A1 HK10109649.4A HK10109649A HK1143154A1 HK 1143154 A1 HK1143154 A1 HK 1143154A1 HK 10109649 A HK10109649 A HK 10109649A HK 1143154 A1 HK1143154 A1 HK 1143154A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyrrolo
- inhibitors
- protein kinase
- pyrimidin derivatives
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97919207P | 2007-10-11 | 2007-10-11 | |
US4786208P | 2008-04-25 | 2008-04-25 | |
PCT/GB2008/050925 WO2009047563A1 (en) | 2007-10-11 | 2008-10-09 | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1143154A1 true HK1143154A1 (zh) | 2010-12-24 |
Family
ID=40251789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10109649.4A HK1143154A1 (zh) | 2007-10-11 | 2010-10-12 | 作為蛋白激酶 抑制劑的吡咯並 嘧啶衍生物 |
Country Status (38)
Country | Link |
---|---|
US (8) | US8101623B2 (zh) |
EP (1) | EP2201012B1 (zh) |
JP (2) | JP4705695B2 (zh) |
KR (1) | KR101494734B1 (zh) |
CN (1) | CN101861321B (zh) |
AR (1) | AR068846A1 (zh) |
AU (1) | AU2008309383B2 (zh) |
BR (1) | BRPI0818533B8 (zh) |
CA (1) | CA2701057C (zh) |
CL (1) | CL2008003023A1 (zh) |
CO (1) | CO6270328A2 (zh) |
CR (1) | CR11359A (zh) |
CU (1) | CU23886B1 (zh) |
CY (1) | CY1116929T1 (zh) |
DK (1) | DK2201012T3 (zh) |
DO (1) | DOP2010000103A (zh) |
EA (1) | EA018512B1 (zh) |
ES (1) | ES2522365T3 (zh) |
GT (1) | GT201000082A (zh) |
HK (1) | HK1143154A1 (zh) |
HN (1) | HN2010000653A (zh) |
HR (1) | HRP20140807T1 (zh) |
IL (1) | IL204721A (zh) |
ME (1) | ME01999B (zh) |
MX (1) | MX2010003927A (zh) |
MY (1) | MY150059A (zh) |
NI (1) | NI201000050A (zh) |
NZ (1) | NZ585261A (zh) |
PE (2) | PE20090964A1 (zh) |
PL (1) | PL2201012T3 (zh) |
PT (1) | PT2201012E (zh) |
RS (1) | RS53552B1 (zh) |
SA (1) | SA08290625B1 (zh) |
SI (1) | SI2201012T1 (zh) |
TW (1) | TWI453021B (zh) |
UY (1) | UY31384A1 (zh) |
WO (1) | WO2009047563A1 (zh) |
ZA (1) | ZA201002318B (zh) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
EP2043655A2 (en) | 2006-04-25 | 2009-04-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
SG174071A1 (en) * | 2006-08-10 | 2011-09-29 | Oncotherapy Science Inc | Genes and polypeptides relating to breast cancers |
JP4705695B2 (ja) | 2007-10-11 | 2011-06-22 | アストラゼネカ アクチボラグ | プロテインキナーゼb阻害剤としてのピロロ[2,3−d]ピリミジン誘導体 |
WO2011002772A1 (en) * | 2009-06-29 | 2011-01-06 | Oncotherapy Science, Inc. | Imidazopyridine derivatives and pbk inhibitors containing the same |
GB201020161D0 (en) | 2010-11-26 | 2011-01-12 | Almac Discovery Ltd | Pharmaceutical compounds |
PL2651417T3 (pl) | 2010-12-16 | 2017-08-31 | Calchan Limited | Pochodne pirolopirymidyny hamujące ASK1 |
JP6100700B2 (ja) | 2011-01-11 | 2017-03-22 | ノバルティス アーゲー | 組合せ |
PL2694056T3 (pl) * | 2011-04-01 | 2020-03-31 | Astrazeneca Ab | Leczenie terapeutyczne |
AU2013205648B2 (en) * | 2011-11-30 | 2015-02-05 | Astrazeneca Ab | Combination treatment |
EP2785349B2 (en) | 2011-11-30 | 2022-11-09 | Astrazeneca AB | Combination treatment of cancer |
AU2013204533B2 (en) * | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
EP2948447B1 (en) | 2013-01-23 | 2016-09-21 | Astrazeneca AB | Chemical compounds |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
JP6295578B2 (ja) * | 2013-09-30 | 2018-03-20 | 凸版印刷株式会社 | 反応容器、核酸解析装置、および核酸解析方法 |
CN105792825A (zh) * | 2013-10-01 | 2016-07-20 | 诺华股份有限公司 | 组合 |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
CN106164066B (zh) | 2014-02-13 | 2020-01-17 | 因赛特公司 | 作为lsd1抑制剂的环丙胺 |
WO2015123424A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
MX2016015613A (es) * | 2014-05-28 | 2017-04-13 | Astrazeneca Ab | Procesos para la preparacion de azd5363 e intermedios novedosos utilizados en el mismo. |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
ES2757948T3 (es) | 2015-04-03 | 2020-04-30 | Incyte Corp | Compuestos heterocíclicos como inhibidores LSD1 |
CR20180152A (es) | 2015-08-12 | 2018-08-09 | Incyte Corp | Sales de un inhibidor de lsd1 |
TW201726140A (zh) | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
KR102664509B1 (ko) | 2016-04-22 | 2024-05-10 | 인사이트 코포레이션 | Lsd1 억제제의 제제 |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
CA3158321A1 (en) | 2019-11-04 | 2021-05-14 | Astrazeneca Ab | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
US20240051964A1 (en) * | 2021-01-04 | 2024-02-15 | Teva Pharmaceuticals International Gmbh | Solid state forms of capivasertib and process for preparation thereof |
WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
CN114601836B (zh) * | 2022-04-12 | 2022-12-06 | 四川大学华西医院 | 一种akt抑制剂在制备治疗乳腺癌的药物中的应用 |
WO2024083716A1 (en) | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
WO2024104561A1 (en) | 2022-11-15 | 2024-05-23 | Astrazeneca Ab | Therapeutic combinations of capivasertib and venetoclax |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL297170A (zh) | 1963-04-04 | 1900-01-01 | ||
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
AU6111298A (en) | 1997-02-12 | 1998-09-08 | Samir M. Hanash | Protein markers for lung cancer and use thereof |
US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
JP3711238B2 (ja) | 1997-08-05 | 2005-11-02 | ファイザー・プロダクツ・インク | 神経ペプチドY受容体アンタゴニストとしての4−アミノピロ−ル(3,2−d)ピリミジン |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
PL345906A1 (en) | 1998-06-04 | 2002-01-14 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
DK1553097T3 (da) | 1999-02-10 | 2010-12-13 | Astrazeneca Ab | Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil |
EP1181296A1 (en) | 1999-06-03 | 2002-02-27 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
PT1676845E (pt) | 1999-11-05 | 2008-08-05 | Astrazeneca Ab | Novos derivados de quinazolina |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
AU3977001A (en) | 2000-02-15 | 2001-08-27 | Sugen Inc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
CN100351253C (zh) | 2000-06-26 | 2007-11-28 | 辉瑞产品公司 | 作为免疫抑制剂的吡咯并[2,3-d]嘧啶化合物 |
WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
AU9378801A (en) | 2000-08-31 | 2002-03-13 | Hoffmann La Roche | Quinazoline derivatives as alpha-1 adrenergic antagonists |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
YU42703A (sh) | 2000-12-01 | 2006-03-03 | Osi Pharmaceuticals Inc. | Jedinjenja specifična za dobijanje adenozinske a1,a2a i a3 receptore i njihove primene |
US6962936B2 (en) * | 2001-04-27 | 2005-11-08 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
DE60305446T4 (de) | 2002-01-07 | 2009-07-09 | Eisai R&D Management Co., Ltd. | Desazapurine und deren verwendung |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
WO2004002531A1 (ja) | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | 血管の収縮または拡張による疾患治療剤 |
US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
AU2003265636A1 (en) | 2002-09-06 | 2004-03-29 | Smithkline Beecham Corporation | Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds |
JP4796301B2 (ja) | 2002-11-08 | 2011-10-19 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | テクネチウム−99m及びレニウムで標識した小型作用剤及び組織、臓器及び腫瘍の画像化方法 |
PL377187A1 (pl) | 2002-12-04 | 2006-01-23 | Eisai R & D Management, Co., Ltd. | Związki ze skondensowanym pierścieniem 1,3-dihydroimidazolowym |
EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
EP1601357A4 (en) | 2003-03-10 | 2007-10-03 | Schering Corp | HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS |
WO2004094426A1 (en) | 2003-04-21 | 2004-11-04 | Ustav Organické Chemie A Biochemie Akademie Ved Ceské Republiky | (purin-6-yl) amino acid and production method thereof |
FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
CA2536954C (en) | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | C-kit modulators and methods of use |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
RU2006121990A (ru) | 2003-11-21 | 2007-12-27 | Эррэй Биофарма Инк. (Us) | Ингибиторы протеинкиназ акт |
WO2005063704A1 (ja) | 2003-12-25 | 2005-07-14 | Ono Pharmaceutical Co., Ltd. | アゼチジン環化合物およびその医薬 |
CA2561977A1 (en) * | 2004-03-30 | 2005-10-13 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
EP1750727A2 (en) * | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
AU2005322085B2 (en) * | 2004-12-28 | 2012-07-19 | Exelixis, Inc. | [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
WO2006091450A1 (en) | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
JP5071374B2 (ja) | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ3阻害剤 |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
CA2635899A1 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
US20090253718A1 (en) | 2006-04-25 | 2009-10-08 | Astex Therapeutics Limited | Pharmaceutical Compounds |
JP2009536620A (ja) | 2006-04-25 | 2009-10-15 | アステックス、セラピューティックス、リミテッド | 医薬組み合わせ物 |
JP2009534456A (ja) * | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
WO2007125320A1 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
EP2043655A2 (en) | 2006-04-25 | 2009-04-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
CN101678022A (zh) | 2006-12-21 | 2010-03-24 | 弗特克斯药品有限公司 | 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物 |
AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
JP4705695B2 (ja) | 2007-10-11 | 2011-06-22 | アストラゼネカ アクチボラグ | プロテインキナーゼb阻害剤としてのピロロ[2,3−d]ピリミジン誘導体 |
-
2008
- 2008-10-09 JP JP2010528485A patent/JP4705695B2/ja active Active
- 2008-10-09 ES ES08806741.8T patent/ES2522365T3/es active Active
- 2008-10-09 MY MYPI2010001617A patent/MY150059A/en unknown
- 2008-10-09 DK DK08806741.8T patent/DK2201012T3/da active
- 2008-10-09 EP EP08806741.8A patent/EP2201012B1/en active Active
- 2008-10-09 WO PCT/GB2008/050925 patent/WO2009047563A1/en active Application Filing
- 2008-10-09 UY UY31384A patent/UY31384A1/es not_active Application Discontinuation
- 2008-10-09 PL PL08806741T patent/PL2201012T3/pl unknown
- 2008-10-09 RS RS20140457A patent/RS53552B1/en unknown
- 2008-10-09 NZ NZ585261A patent/NZ585261A/en unknown
- 2008-10-09 EA EA201000552A patent/EA018512B1/ru not_active IP Right Cessation
- 2008-10-09 KR KR1020107010107A patent/KR101494734B1/ko active IP Right Grant
- 2008-10-09 MX MX2010003927A patent/MX2010003927A/es active IP Right Grant
- 2008-10-09 CA CA2701057A patent/CA2701057C/en active Active
- 2008-10-09 BR BRPI0818533A patent/BRPI0818533B8/pt active IP Right Grant
- 2008-10-09 ME MEP-2014-102A patent/ME01999B/me unknown
- 2008-10-09 SI SI200831281T patent/SI2201012T1/sl unknown
- 2008-10-09 AU AU2008309383A patent/AU2008309383B2/en active Active
- 2008-10-09 PT PT88067418T patent/PT2201012E/pt unknown
- 2008-10-09 TW TW097139021A patent/TWI453021B/zh active
- 2008-10-09 CN CN200880116651XA patent/CN101861321B/zh active Active
- 2008-10-10 CL CL2008003023A patent/CL2008003023A1/es unknown
- 2008-10-10 PE PE2008001748A patent/PE20090964A1/es active IP Right Grant
- 2008-10-10 AR ARP080104450A patent/AR068846A1/es active IP Right Grant
- 2008-10-10 PE PE2012002041A patent/PE20130152A1/es not_active Application Discontinuation
- 2008-10-10 US US12/249,477 patent/US8101623B2/en active Active
- 2008-10-11 SA SA8290625A patent/SA08290625B1/ar unknown
-
2010
- 2010-03-25 IL IL204721A patent/IL204721A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02318A patent/ZA201002318B/en unknown
- 2010-04-09 GT GT201000082A patent/GT201000082A/es unknown
- 2010-04-09 DO DO2010000103A patent/DOP2010000103A/es unknown
- 2010-04-09 HN HN2010000653A patent/HN2010000653A/es unknown
- 2010-04-09 CU CU20100062A patent/CU23886B1/es active IP Right Grant
- 2010-04-09 NI NI201000050A patent/NI201000050A/es unknown
- 2010-04-09 CR CR11359A patent/CR11359A/es unknown
- 2010-05-06 CO CO10054272A patent/CO6270328A2/es active IP Right Grant
- 2010-10-12 HK HK10109649.4A patent/HK1143154A1/zh unknown
-
2011
- 2011-03-09 JP JP2011051117A patent/JP5330430B2/ja active Active
- 2011-12-13 US US13/324,191 patent/US20120190679A1/en not_active Abandoned
-
2014
- 2014-08-26 HR HRP20140807AT patent/HRP20140807T1/hr unknown
- 2014-08-28 CY CY20141100689T patent/CY1116929T1/el unknown
-
2015
- 2015-02-19 US US14/626,303 patent/US9492453B2/en active Active
-
2016
- 2016-11-15 US US15/351,481 patent/US10059714B2/en active Active
-
2018
- 2018-07-06 US US16/028,979 patent/US10654855B2/en active Active
-
2020
- 2020-04-07 US US16/841,820 patent/US11236095B2/en active Active
-
2021
- 2021-12-16 US US17/644,654 patent/US11760760B2/en active Active
-
2023
- 2023-08-04 US US18/365,286 patent/US20240109902A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1143154A1 (zh) | 作為蛋白激酶 抑制劑的吡咯並 嘧啶衍生物 | |
IL278119B (en) | Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors | |
HRP20181912T1 (hr) | Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze | |
SI1893612T1 (sl) | Pirolo b piridin derivati kot protein kinazni inhibitorji | |
HK1160116A1 (zh) | 吡咯並 嘧啶化合物 | |
ZA201200982B (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
IL195238A0 (en) | Pyrazolo [1,5-a]pyrimidines as cdk inhibitors | |
ZA201004368B (en) | Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors | |
ZA200803173B (en) | Pyrazolo [4,3-d] Pyrimidin-5-yl) Derivative used as PDE5 Inhibitors |